---
schema_version: "secwatch.filing_event.v1"
accession: "0001965040-24-000041"
form_type: "8-K"
ticker: "FTRE"
cik: "0001965040"
company_name: "Fortrea Holdings Inc."
filed_at: "2024-06-04T23:59:59+00:00"
generated_at: "2026-06-01T06:37:40.391549+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Fortrea completes divestiture of Endpoint Clinical and Patient Access to Arsenal for $295M plus $45M milestone

## Summary
- Final purchase price $295M paid at closing plus $45M upon achieving transition milestones.
- Net proceeds to be used to reduce a portion of Fortrea's overall debt.
- Sam Osman appointed CEO of the new entities; Ray Hill named chairman.
- Fortrea becomes a pure-play clinical CRO after the divestiture.

## SEC filing metadata
- accession: 0001965040-24-000041
- form_type: 8-K
- ticker: FTRE
- cik: 0001965040
- company_name: Fortrea Holdings Inc.
- filed_at: 2024-06-04T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1965040/000196504024000041/0001965040-24-000041-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1965040/000196504024000041/ftre-20240603.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001965040-24-000041
- JSON: https://secwatch.observer/filing/0001965040-24-000041.json
- Plain text: https://secwatch.observer/filing/0001965040-24-000041.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.